| Disease | A STUDY INCLUDING 2 MAJOR PARTS, WITH THE FIRST PART INVESTIGATING THE EFFECTS OF SINGLE DOSES OF 80 AND 160 MG OF EGB 761 VERSUS PLACEBO AND THE SECOND PART INVESTIGATING THE SUBACUTE EFFECTS (5 D OF TREATMENT) OF DAILY DOSES OF 160 MG OF EGB
761. THE FIRST PART USED A BALANCED DOUBLE-BLIND DESIGN, WHEREAS THE SECOND PART USED A SINGLE-BLIND DESIGN. ONE DAY OF WASH-OUT WAS OBSERVED BETWEEN EACH RECORDING DAY IN PART ONE OF THIS STUDY, AND BEFORE THE BEGINNING OF PART TWO. FOR EACH
RECORDING DAY, SPONTANEOUS EEG AND ERP RECORDINGS WERE CARRIED OUT PRIOR TO DRUG ADMINISTRATION (9:00 AM), AND 0.5, 1, 1.5, 2, 3, 4, 5 AND 6 HR AFTER DRUG ADMINISTRATION. EEG DATA CONFIRMED THAT EGB 761 HAS A NOOTROPIC PROFILE, WITH IMPROVEMENTS
IN THE VIGILANCE LEVEL, WITH BENEFICAL EFFECTS ON COGNITIVE SKILLS, LIKE MEMORY.
A COMMERCIAL PRODUCT, EGB-761, WAS USED. |